Physiologically-based pharmacokinetic simulations in pharmacotherapy: selection of the optimal administration route for exogenous melatonin

The benefits of melatonin on human body are drawing increasing attention from several researchers in different fields. While its role as cure for sleep disturbances (e.g., jet lag, insomnia) is well documented and established, new functions in physiological and pathophysiological processes are emerg...

Full description

Saved in:
Bibliographic Details
Main Authors: Adriana Savoca (Author), Davide Manca (Author)
Format: Book
Published: International Association of Physical Chemists (IAPC), 2019-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_ea28f205036e47b4aa1bf185228baf6e
042 |a dc 
100 1 0 |a Adriana Savoca  |e author 
700 1 0 |a Davide Manca  |e author 
245 0 0 |a Physiologically-based pharmacokinetic simulations in pharmacotherapy: selection of the optimal administration route for exogenous melatonin 
260 |b International Association of Physical Chemists (IAPC),   |c 2019-02-01T00:00:00Z. 
500 |a 1848-7718 
500 |a 10.5599/admet.625 
520 |a The benefits of melatonin on human body are drawing increasing attention from several researchers in different fields. While its role as cure for sleep disturbances (e.g., jet lag, insomnia) is well documented and established, new functions in physiological and pathophysiological processes are emerging. To investigate these effects, there is need for the characterization of melatonin transport processes in the body and resulting pharmacokinetics. Although recent works propose physiologically-based pharmacokinetic modelling of melatonin, no work has yet highlighted the potential of PBPK simulations to shed light on melatonin pharmacokinetic aspects and discrimination among administration routes. This paper presents, validates, and discusses a versatile PBPK model featuring different ways of administration and compares the resulting pharmacokinetic profiles of intravenous, oral, and transdermal administration, with the goal of understanding which is the optimal route to achieve either physiological and/or supraphysiological melatonin levels. 
546 |a EN 
690 |a Melatonin 
690 |a PBPK 
690 |a administration route 
690 |a transdermal 
690 |a controlled release 
690 |a simulation 
690 |a clinical efficacy. 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n ADMET and DMPK, Vol 7, Iss 1, Pp 44-59 (2019) 
787 0 |n http://pub.iapchem.org/ojs/index.php/admet/article/view/625 
787 0 |n https://doaj.org/toc/1848-7718 
856 4 1 |u https://doaj.org/article/ea28f205036e47b4aa1bf185228baf6e  |z Connect to this object online.